Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novavax

COVID-19 booster uptake remains low, despite growing evidence they’re as good as older shots

DENVER — More than two months into the campaign to get people to take updated COVID-19 boosters, only about 8% of people who are eligible have received the shot, though about 23% of those 65 and older have, according to Centers for Disease Control and Prevention estimates.

The Denver Post

Novavax says Omicron shot shows strong immune response as second booster

Vaccine maker Novavax Inc said on Tuesday its COVID-19 shot retooled against the Omicron BA.1 variant showed a strong immune response as the fourth dose and met the main goal of strain change in a late-stage study.

Reuters

US clears Novavax COVID booster dose

The Food and Drug Administration has authorized a booster dose of the COVID-19 vaccine made by Novavax

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

What vaccine can you get, based on your age? These are the recommended COVID-19 vaccines for each age group

More than 14.2 million Australians over the age of 16 have now received three or more doses. So which are the best vaccines for each age group?

ABC News

Pharma Giants Moderna And Novavax Trend Lower In This Pattern: What's Going On?

Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) were trading down over 2% and 4%, respectively in the premarket Friday despite both stocks showing signs a bounce could be in the cards.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2022

Upgrades

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Benzinga

Novavax Covid vaccine approved for 12 to 17 year olds in Britain

Health authorities say the vaccine is safe and effective in this age group

Evening Standard

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Benzinga

Morning Digest | India finishes 4th as Commonwealth Games closes; BJP says it will stand by ally JD(U), and more

A select list of stories to read before you start your day

The Hindu

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Reuters

EU says Novavax COVID shot must carry heart side-effect warning

The European Medicines Agency (EMA) is recommending Novavax's COVID-19 vaccine carry a warning of the possibility of two types of heart inflammation, an added burden for a shot that has so far failed to win wide uptake.

Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

WEKU

The CDC endorses Novavax, a more traditional COVID vaccine, for adults

Adults who haven't gotten any COVID-19 shots should consider the new option, the agency said Tuesday. The spike protein vaccine is more typical than the mRNA types being broadly used against COVID.

Tribune News Service

Novavax COVID shot for adults gains CDC advisers’ backing

Novavax Inc.’s shares surged after its COVID-19 vaccine won backing from a panel of U.S. public health advisers, a crucial step in providing officials with another tool against the virus as cases start to rise again.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap of Tuesday's Biotech Catalysts - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy.

The Independent UK

CDC endorses new Novavax Covid vaccine

Two-dose shot will becomes fourth one to gain full approval later this week

The Independent UK

CDC advisers endorse more traditional Novavax COVID shot

Government advisers say U.S. adults who haven’t gotten any COVID-19 shots yet should consider a new option from Novavax

StockNews.com

Is Novavax a Buy, Sell, or Hold Following FDA Decision?

Despite the FDA authorization of Novavax’s (NVAX) two-dose vaccine, the possible side effects and slow vaccine uptake keep the stock under pressure. So, let’s evaluate if it is worth adding the stock to one’s portfolio now. Read on….

ABC News

Australia has ordered millions more COVID vaccines than it needs. What are the options to deal with them?

Australia has used less than a quarter of the hundreds of millions of COVID-19 vaccine doses it bought. What will happen to the rest?

Benzinga

Novavax (NVAX) Down As EU Adds Side Effects To COVID Jab Label

Shares of Novavax (NASDAQ: NVAX) fell 26.2% on Jul 14, after the European Medicines Agency's (TSE: EMA) Pharmacovigilance Risk Assessment Committee ("PRAC") updated the product label of Nuvaxovid, the company's COVID-19 vaccine, to include some potential side effects like severe aller

Benzinga

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures

Here's a roundup of top developments in the biotech space over the last 24 hours:

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Bharatiya Janata Party

Food and Drug Administration

322 stories

Snowflake

312 stories

Centers for Disease Control and Prevention

304 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.